Beacon Therapeutics to Participate in the Jefferies Global Healthcare Conference

LONDON and CAMBRIDGE, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading clinical-stage biotechnology company with a mission to save and restore vision in people with rare and prevalent ocular diseases, today announced that members of its management team will participate in the Jefferies Global Healthcare Conference being held November 17-20, 2025 in London, UK.

The Company completed enrollment in its pivotal VISTA trial evaluating lead ocular gene therapy candidate, laru-zova, for the treatment of X-linked retinitis pigmentosa (XLRP) in July 2025 and expects twelve-month topline data in the second half of 2026.

About Beacon Therapeutics
Beacon Therapeutics is a clinical-stage biotechnology company dedicated to saving and restoring sight for people living with rare and prevalent ocular diseases. The Company is harnessing the transformative power of gene therapy to deliver the most meaningful outcomes for severe ocular diseases. Beacon’s pipeline currently targets devastating blinding retinal diseases such as X-linked retinitis pigmentosa (XLRP) and geographic atrophy.

Beacon Therapeutics’ investors include Forbion, Syncona Limited, Oxford Science Enterprises, TCGX and Advent Life Sciences, among others. Learn more about Beacon Therapeutics at beacontx.com and follow on LinkedIn for more updates.

Contact:
[email protected]

Media & Investors:
[email protected]

Source: Beacon Therapeutics (USA), Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• 3 E Network Enters into $1M Private Placement to CEO-Led Entity at $1.426 Per Share
• Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference
• Brixton Metals Drills 6,199 g/t Silver over 1.00 m including 0.50 m of 12,386 g/t Silver in Hole 432 at its Langis Project in Ontario